News Release

Retrotransposon DNA zip code for myeloma cell internalization

“GT is a fascinating evolutionary phenomenon observed in lower species and humans, albeit with differing impacts and mechanisms”

Peer-Reviewed Publication

Impact Journals LLC

Unveiling retrotransposon-derived DNA zip code for myeloma cell internalization

image: 

Figure 2. Diagrammatic representation of kodikaz therapeutic solutions’ zip-code technology application to various human diseases.

view more 

Credit: 2024 Puvvula et al.

“GT is a fascinating evolutionary phenomenon observed in lower species and humans, albeit with differing impacts and mechanisms.”

BUFFALO, NY- August 9, 2024 – A new editorial was published in Oncoscience (Volume 11) on July 13, 2024, entitled, “Unveiling retrotransposon-derived DNA zip code for myeloma cell internalization.”

The complex interplay between extracellular genetic material and the tumor's genetic landscape presents a significant challenge in grasping cancer evolution, tumor genetic heterogeneity, and treatment response. Earlier research has revealed the role of circulating tumor DNA (ctDNA) in mediating the gene expression among cancer cells, offering new insights into a previously under-explored aspect of genetic exchange in human malignancies.

In this editorial, researchers Pavan Kumar Puvvula, Anthony Johnson, and Leon Bernal-Mizrachi from Kodikaz Therapeutic Solutions, Inc. and Winship Cancer Institute of Emory University delve into the findings of several studies that elucidate the mechanisms underlying ctDNA-driven gene transfer (GT) and its potential implications for cancer biology and therapy.

“GT is a fascinating evolutionary phenomenon observed in lower species and humans, albeit with differing impacts and mechanisms.”

This research highlights the importance of retrotransposon-derived DNA zip codes in myeloma cell biology and their interactions with the tumor microenvironment.

“Collaboration between academia, industry, and regulatory agencies will be essential for translating zip-code technology from the bench to the bedside and realizing its full potential in improving patient outcomes and advancing human health.”

Continue reading: DOI: https://doi.org/10.18632/oncoscience.606 

Corresponding authors - Pavan Kumar Puvvula - pavan@kodikaz.com, and Leon Bernal-Mizrachi - lbernal@emory.edu

Keywords: cancer, myeloma, non-viral gene therapy, retrotransposons, Rab5a, Clathrin, Syntaxin-6, DNA internalization, Zip-code

About Oncoscience

Oncoscience is a peer-reviewed, open-access, traditional journal covering the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. This journal has a special mission: Freeing oncology from publication cost. It is free for the readers and the authors.

To learn more about Oncoscience, visit Oncoscience.us and connect with us on social media:

For media inquiries, please contact media@impactjournals.com.

Oncoscience Journal Office
6666 East Quaker St., Suite 1
Orchard Park, NY 14127
Phone: 1-800-922-0957, option 4


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.